Richard Jimenez, MD
Rheumatology · Bothell, WANPI 1366484040
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,239 of the $155,308 with a category attached, or 63.9%. 36 manufacturers reported payments, led by Amgen at 37.3% of the total. Reporting peaked in 2019 at $72,920 and has fallen 80.2% since, to $14,446 in 2025. Among rheumatology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 919 payments — averaging $169.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$58K
- Novartis$29K
- Bristol Myers Squibb$18K
- AbbVie$15K
- Johnson & Johnson$10K
- Mallinckrodt Enterprises LLC$9K
- plus $17K from 30 others
Across 62 payments — averaging $3195.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$122K
- AbbVie$76K
What the payments were for
- Consulting fees$23,99615%
- Speaking & faculty fees$99,23964%
- Travel & lodging$12,6558%
- Food & beverage$19,23212%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 200 | $57,985 |
| Novartis | 79 | $28,598 |
| Bristol Myers Squibb | 38 | $18,147 |
| AbbVie | 170 | $14,908 |
| Johnson & Johnson | 111 | $9,516 |
| Mallinckrodt Enterprises LLC | 17 | $9,437 |
| Kyowa Kirin, Inc. | 9 | $6,629 |
| AstraZeneca(2 entities) | 36 | $3,184 |
| Mallinckrodt Hospital Products Inc. | 3 | $1,738 |
| UCB, Inc. | 29 | $884 |
| E.r. Squibb & Sons, L.L.C. | 42 | $600 |
| GSK | 27 | $597 |
| Lilly USA, LLC | 25 | $583 |
| Sobi, Inc | 18 | $430 |
| Pfizer | 32 | $418 |
| Radius Health, Inc. | 18 | $287 |
| Genentech USA, Inc. | 16 | $264 |
| Boehringer Ingelheim | 8 | $192 |
| Sanofi | 6 | $178 |
| Aurinia Pharma U.S., Inc. | 5 | $110 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $104 |
| Hikma Pharmaceuticals USA | 5 | $74 |
| ANI Pharmaceuticals, Inc. | 3 | $73 |
| Regeneron Healthcare Solutions, Inc. | 2 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Sandoz | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Sentynl Therapeutics, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Bioventus LLC | 1 | $13 |
| Janssen Scientific Affairs, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,308 in reported general payments places this provider in the 95th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 53 | $332,616 |
| Humira(Cf) PenAdalimumab | 42 | $298,117 |
| EnbrelEtanercept | 32 | $255,537 |
| OrenciaAbatacept | 27 | $158,525 |
| Enbrel MiniEtanercept | 16 | $119,841 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $97,105 |
| Cosentyx (2 Syringes)Secukinumab | 13 | $94,771 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $74,536 |
| Hydroxychloroquine Sulfate | 171 | $6,159 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 123 | $3,754 |
| Cevimeline Hcl | 29 | $2,899 |
| Celecoxib | 127 | $2,762 |
| MethotrexateMethotrexate Sodium | 142 | $2,392 |
| Dexlansoprazole DrDexlansoprazole | 12 | $1,979 |
| Fentanyl | 20 | $1,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $14,908 | $332,61653 claims |
| AmgenEnbrel | $57,985 | $255,53732 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $600 | $158,52527 claims |
| NovartisCosentyx (2 Syringes) | $28,598 | $94,77113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $41 | $74,53615 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $74 | $1,02017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 157 rheumatology providers in Washington.
Other rheumatology in Bothell
- Jeff PetersonBothell$2.3M
- Andrew SolomonBothell$47K
- Stanford PengSeattle$3.5M
- Philip MeaseSeattle$2.1M
- Robert EttlingerTacoma$232K
- Howard KenneySpokane$132K
- Arinola DadaBellevue$69K
- Verlene GauthierCovington$63K
- Jane BucknerSeattle$57K
- Viviane BuninBellevue$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.